3G0 Stock Chart & Stats
€2.44
€0.03(1.25%)
At close: 4:00 PM EDT
€2.44
€0.03(1.25%)
Day’s Range― - ―
52-Week Range€2.20 - €5.32
Previous CloseN/A
Volume0.00
Average Volume (3M)195.00
Market Cap
€493.98M
Enterprise Value€273.45
Total Cash (Recent Filing)€326.32M
Total Debt (Recent Filing)€35.75M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 10, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding194,474,150
10 Day Avg. Volume554
30 Day Avg. Volume195
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.46Price Target Upside492.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.53
Revenue Forecast (FY)€1.65K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet & Pro Forma Cash RunwayA debt-free balance sheet and ~$535M pro forma cash materially increase Altimmune’s ability to fund global Phase III start‑up and multi-year trials without immediate dilutive financing. This financial flexibility supports longer-term execution, CRO commitments, and clinical supply obligations through registrational milestones.
Regulatory Recognition — Breakthrough TherapyBreakthrough Therapy designation and alignment with FDA/EMA on PERFORMA protocol de‑risks regulatory pathway, enables more frequent regulator engagement, and can accelerate review timelines. This structural recognition raises the program’s probability of efficient development and potential expedited access if trials confirm benefit.
Positive Phase II Signals Across IndicationsRobust Phase II efficacy and tolerability in RECLAIM (AUD) plus prior IMPACT MASH signals strengthen pemvidutide’s value proposition across metabolic and liver indications. Consistent biomarker and clinical endpoints improve confidence in translatability to registrational studies and increase partnership and label expansion optionality.
Bears Say
Persistent Cash Burn And Weak Cash GenerationOngoing negative operating and free cash flow create structural reliance on capital markets or partnerships until commercial revenue emerges. Despite pro forma proceeds, sustained development costs for multi‑year Phase III programs mean dilution or new funding rounds remain likely if timelines extend or additional programs are pursued.
Long Phase III Timelines To Registrational ReadoutA 52‑week biopsy primary endpoint and a multi‑year global Phase III create an extended horizon to potential approval and revenue, raising execution risk and capital consumption over time. Long timelines magnify the impact of operational setbacks and allow competitors more opportunity to capture market share before launch.
Intense Competitive LandscapeA crowded GLP‑1/dual‑ and triple‑agonist field heightens the need for clear clinical differentiation on tolerability and liver efficacy. Competitive entrants with established brands or broader efficacy could limit market share and pricing power, requiring stronger post‑approval evidence or strategic partnerships to secure commercial success.
Altimmune News
3G0 FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was €2.20 and its highest was €5.32 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is €493.98M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Nov 10, 2026 which is in 88 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Aug 12, 2026. The company reported -€0.104 earnings per share for the quarter, beating the consensus estimate of -€0.118 by €0.014.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune does not currently pay dividends.
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.12.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -€0.104 in its last earnings report, beating expectations of -€0.118. Following the earnings report the stock price went up 0.385%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in DE:3G0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.46 (492.69% Upside)
€14.46 (492.69% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €38.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.97%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
3G0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all DE:3G0 earnings summaries3G0 Stock 12 Month Forecast
Average Price Target
€14.46
▲(492.69% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―